Esperion Therapeutics Company Profile (NASDAQ:ESPR)

Analyst Ratings

Consensus Ratings for Esperion Therapeutics (NASDAQ:ESPR) (?)
Ratings Breakdown: 2 Sell Rating(s), 6 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Hold (Score: 2.23)
Consensus Price Target: $26.42 (142.35% upside)

Analysts' Ratings History for Esperion Therapeutics (NASDAQ:ESPR)
Show:
DateFirmActionRatingPrice TargetActions
7/6/2016Credit Suisse Group AGReiterated RatingSell$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/5/2016WallachBeth CapitalDowngradeBuy -> Hold$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Stifel NicolausDowngradeNeutral -> Underperform$23.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Chardan CapitalReiterated RatingHold$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Needham & Company LLCReiterated RatingBuy$77.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Barclays PLCDowngradeOverweight -> Equal Weight$28.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Citigroup Inc.Reiterated RatingBuy$36.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Lake Street CapitalLower Price TargetBuy$80.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$30.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/29/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$50.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016JMP SecuritiesReiterated RatingBuy$67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2015Bank of America Corp.Reiterated RatingBuy$65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/17/2015FIXReiterated RatingaddView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Esperion Therapeutics (NASDAQ:ESPR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/4/2016Q116($0.74)($0.65)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q4($0.61)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q3($0.60)($0.57)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.58)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.48)($0.56)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015($0.54)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214$0.60$0.60ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.62)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2014($0.50)($0.63)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Esperion Therapeutics (NASDAQ:ESPR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.82)($0.82)($0.82)
Q2 20161($0.78)($0.78)($0.78)
Q3 20161($1.02)($1.02)($1.02)
Q4 20161($1.28)($1.28)($1.28)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Esperion Therapeutics (NASDAQ:ESPR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Esperion Therapeutics (NASDAQ:ESPR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/6/2016Mark E McgovernDirectorBuy5,000$10.00$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2016Timothy M MaylebenCEOBuy7,000$14.85$103,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Gilbert S OmennDirectorBuy5,000$15.28$76,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2016Timothy M MaylebenCEOBuy3,600$15.88$57,168.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Timothy M MaylebenCEOBuy7,200$14.08$101,376.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2015Dov A Md GoldsteinDirectorSell217,469$108.22$23,534,495.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Patrick G EnrightDirectorSell487,130$32.78$15,968,121.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2014Parters Vii L P DomainMajor ShareholderBuy500,000$20.00$10,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Longitude Capital Partners, LlMajor ShareholderSell11,927$30.04$358,287.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Brian H DoveyMajor ShareholderBuy285,714$14.00$3,999,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Daniel JanneyDirectorBuy235,714$14.00$3,299,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Roger S NewtonChairmanBuy42,346$14.00$592,844.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Timothy M MaylebenCEOBuy5,000$14.00$70,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Esperion Therapeutics (NASDAQ:ESPR)
DateHeadline
07/22/16 06:01 AMEsperion Therapeutics Inc Can't Be More Safe. Trades Significantly Higher - Consumer Eagle
07/21/16 07:26 AMEsperion Therapeutics Incorporated (NASDAQ:ESPR) Shorted Shares Decreased By 1.99% - Press Telegraph
07/20/16 06:12 AMHow Analysts Rated Esperion Therapeutics Inc (NASDAQ:ESPR) Last Week? - Consumer Eagle
07/20/16 06:12 AMEquity Roundup: Stock Performance Focus on Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Press Telegraph
07/17/16 03:34 PMIncreased Volatility Noted on Shares of: Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Engelwood Daily
07/16/16 07:18 AMShares Experiencing a Downtrend: Esperion Therapeutics, Inc. (NASDAQ:ESPR) - TGP
07/16/16 07:18 AMEsperion Therapeutics Inc. (ESPR) Jumps 7.52% on July 15 - Equities.com
07/14/16 09:14 PMEsperion Director buys 4,400 shares
07/14/16 09:14 PMInvestor News: Investigation of Esperion Therapeutics Inc (NASDAQ:ESPR) over potential Misconduct
07/14/16 04:00 PMEsperion Therapeutics Inc Realized Volatility Hits Extreme Level - CML News
07/13/16 04:12 PMInvestor News: Investigation of Esperion Therapeutics Inc (NASDAQ:ESPR) over potential Misconduct - GroundReport
07/13/16 04:12 PMBroker Outlook For Esperion Therapeutics, Inc. (ESPR) - Fiscal Standard
07/12/16 08:16 AMTrading Performance and Target Watch for Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Press Telegraph
07/12/16 08:16 AMWallachbeth Downgrades Esperion Therapeutics Inc to Hold - TheFounders Daily
07/11/16 03:54 PMThese Five Stocks Have Gotten A Lot Of Attention From Analysts
07/11/16 08:42 AMCompany Stock Focus for Esperion Therapeutics, Inc. (NASDAQ:ESPR): Which Way Will Shares Head? - Press Telegraph
07/10/16 03:40 PMNext Weeks Broker Price Targets For Esperion Therapeutics, Inc. (ESPR) - Fiscal Standard
07/09/16 07:21 AMEsperion Therapeutics Inc. (ESPR) Jumps 6.17% on July 08 - Equities.com
07/08/16 03:53 PMEsperion Therapeutics Inc (NASDAQ:ESPR) Stock Sentiment Improves - Press Telegraph
07/08/16 03:53 PMBeleaguered Esperion Therapeutics Inc. (ESPR) and Two Other Struggling Companies Register Insider Buying - Insider Monkey (blog)
07/08/16 10:15 AMBeleaguered Esperion Therapeutics Inc. (ESPR) and Two Other Struggling Companies Register Insider Buying -
07/08/16 06:26 AMEsperion Therapeutics, Inc. Stock Momentum Hits Extreme Weakness - CML News
07/07/16 09:04 PMBrokers Issue Average Price Target Of 32.85 On Esperion Therapeutics, Inc. (ESPR) - Fiscal Standard
07/07/16 03:55 PMInvestigation for Investors of Esperion Therapeutics Inc (NASDAQ:ESPR) Announced - Digital Journal
07/07/16 06:10 AMEsperion Therapeutics Inc. (ESPR) is Trading Lower on Unusual Volume for July 05 - Equities.com
07/06/16 09:43 PMInsiders Increasing Positions in: Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Press Telegraph
07/06/16 08:37 AMStock Rating Watch and Earnings Insight for Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Press Telegraph
07/05/16 03:46 PMTrend Analysis Report: NorthStar Asset Management (NSAM), Esperion Therapeutics (NASDAQ:ESPR), CME ... - iStreetWire
07/05/16 08:38 AMFXCM Inc. (NYSE:FXCM) went down -4.99%: Esperion Therapeutics, Inc. (NASDAQ:ESPR), Vodafone Group Plc (ADR ... - KC Register
07/05/16 08:01 AMMorning Movers: Tesla Tanks on Delivery Miss; Rowan Sinks -
07/05/16 07:37 AMEsperion Therapeutics downgraded by WallachBeth -
07/02/16 05:55 AMWatching Unusual Volume for: Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Engelwood Daily
07/01/16 06:37 AMEsperion Therapeutics Inc. (ESPR) Hits New 52-week Low During June 29 Session - Equities.com
06/30/16 04:07 PMEsperion Therapeutics Inc. (ESPR) Plunged To A New Low After ETC-1002 Update
06/30/16 04:07 PMEsperion Therapeutics (NASDAQ:ESPR) target price bumped down to $25 as covered today by Needham
06/30/16 06:39 AMEsperion Therapeutics, Inc. (NASDAQ:ESPR) Company Rating and Target Watch - Telanagana Press
06/30/16 06:39 AMRecent Analysts Rating Overview: Esperion Therapeutics, Inc. (NASDAQ:ESPR) , UnitedHealth Group Incorporated ... - Street Updates
06/29/16 08:51 PMEsperion Therapeutics (NASDAQ:ESPR) target price bumped down to $15 as reported today by JP Morgan
06/29/16 08:51 PMAnalyst Downgrades: Esperion Therapeutics Inc, Nike Inc, and Autoliv Inc.
06/29/16 08:51 PMEsperion Therapeutics Shares Crash Down On FDA Rejection
06/29/16 08:51 PMEsperion (ESPR) Offers Updates on LDL-Lowering Candidate
06/29/16 08:51 PMEsperion Therapeutics Inc. (ESPR) Has Dropped To A New Low On FDA News
06/29/16 05:46 PMAnalysts At Chardan See A 'Pattern Of Missed Guidance' For Esperion Therapeutics - Chardan Capital analyst Gbola Amusa offered commentary on Esperion Therapeutics Inc (NASDAQ: ESPR) Wednesday morning following troubling company news related to the company's bempedoic acid. Amusa suggested caution in the name is warranted and noted more than a handful of points which should give pause to investors looking to get involved. The most notable came argued "the release continued what to us is a pattern of missed guidance for Esperion." The Chardan analyst highlighted six other preliminary concerns. "After ...Full story available on Benzinga.com
06/29/16 03:50 PMActive Shares in Focus : Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Telanagana Press
06/29/16 03:50 PMWatching Stock Volatility for: Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Engelwood Daily
06/29/16 03:50 PMEsperion Therapeutics Inc 42.9% Potential Upside Now Implied by RBC Capital Mkts - DirectorsTalk Interviews
06/29/16 03:50 PMWednesday Morning's Biotech Insights: Galena Biopharma Inc (GALE), Esperion Therapeutics Inc (ESPR), Lipocine Inc ... - Smarter Analyst
06/29/16 03:50 PMEsperion Therapeutics Inc. (ESPR) Jumps 8.3% on June 28 - Equities.com
06/29/16 12:40 PMEsperion Therapeutics Inc Sinks After FDA Says, "Ask Us in 2019" - The FDA leaves the biotech hanging.
06/29/16 06:36 AMEsperion Therapeutics Inc. (ESPR) Is Falling On FDA News - RTT News

Social

About Esperion Therapeutics

Esperion Therapeutics logoEsperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company's segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company's lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ESPR
  • CUSIP:
Key Metrics:
  • Previous Close: $10.99
  • 50 Day Moving Average: $13.47
  • 200 Day Moving Average: $15.52
  • P/E Ratio: N/A
  • P/E Growth: 0.56
  • Market Cap: $245.60M
  • Beta: 2.01
  • Current Year EPS Consensus Estimate: $-3.79 EPS
  • Next Year EPS Consensus Estimate: $-4.05 EPS
Additional Links:
Esperion Therapeutics (NASDAQ:ESPR) Chart for Wednesday, July, 27, 2016